BSE filing, NSE: APLLTD. Summary written from the filing by ALFA Finder's alert engine.
Alembic Pharmaceuticals Ltd: key numbers
- Share price
- ₹782.80
- Market cap
- ₹15,387 Cr
- Revenue (annual)
- ₹7,345 Cr
- Net profit (annual)
- ₹674.8 Cr
- P/E (TTM)
- 22.2×Sector 46.1×
- Promoter holding
- 69.87%+0.00% QoQ
- FII holding
- 4.55%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Alembic Pharmaceuticals Ltd
All →Alembic Pharmaceuticals Board Meeting Date
Alembic Pharmaceuticals scheduled its board meeting for November 4, 2026, to consider unaudited Q1/H1 FY27 results. Trading window re-opens 48 hours post-declaration.
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.26 Cr
Alembic Pharmaceuticals' subsidiary, Alembic Global Holding SA, incorporated a new wholly-owned subsidiary, Alvesta Pharmaceuticals FZCO, in the UAE for Rs. 0.26 Crore.
- Value
- ₹0.26 Cr
Alembic Pharmaceuticals Merger & Restructuring Worth ₹0.23 Cr
Alembic Pharmaceuticals' wholly-owned subsidiary, Alembic Global Holding SA, incorporated a new step-down subsidiary, Alvesta Pharmaceuticals FZCO, in Dubai for AED 1 Lakh (approx. ₹0.23 Crore).
- Value
- ₹0.23 Cr
Alembic Pharmaceuticals Regulatory Approval
Alembic Pharmaceuticals received USFDA final approval for Ciprofloxacin and Dexamethasone Otic Suspension USP. This drug is therapeutically equivalent to the reference product Ciprodex Otic Suspension.
Alembic Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern under SEBI Regulation 31(1)(b) for the period ended September 30, 2026.
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr